Figure 2.

Composite endpoints of patients achieving HbA1c reductions >0.5% for the A, basal insulin subgroup or B, overall study population and patients achieving HbA1c <7.0% without documented symptomatic hypoglycemia, without body weight gain, and without documented symptomatic hypoglycemia or body weight gain for the C, basal insulin subgroup and D, overall study population. ^aProportion difference (95% confidence interval) between treatment groups calculated using Cochran‐Mantel‐Haenszel model